Cargando…

Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities

SIMPLE SUMMARY: Pancreatic cancer is a leading cause of cancer death worldwide. In the majority of patients, cancers are diagnosed at advanced stages of disease and are resistant to current treatments. Therefore, more effective and less toxic therapeutic agents are urgently needed. Monoclonal antibo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Arias-Pinilla, Gustavo A., Modjtahedi, Helmout
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8068268/ https://www.ncbi.nlm.nih.gov/pubmed/33917882 http://dx.doi.org/10.3390/cancers13081781

Ejemplares similares

Development of novel monoclonal antibodies against CD109 overexpressed in human pancreatic cancer
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2018)

Development and application of two novel monoclonal antibodies against overexpressed CD26 and integrin α3 in human pancreatic cancer
por: Arias-Pinilla, Gustavo A., et al.
Publicado: (2020)

Synergistic activity of agents targeting growth factor receptors, CDKs and downstream signaling molecules in a panel of pancreatic cancer cell lines and the identification of antagonistic combinations: Implications for future clinical trials in pancreatic cancer
por: Khan, Tanzeel, et al.
Publicado: (2020)

Biotherapeutics: Challenges and Opportunities for Predictive Toxicology of Monoclonal Antibodies
por: Johnson, Dale E.
Publicado: (2018)

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use
por: Sewell, Fiona, et al.
Publicado: (2017)

Therapeutic resistance in pancreatic ductal adenocarcinoma: Current challenges and future opportunities
por: Jain, Aditi, et al.
Publicado: (2021)

Acquired resistance of pancreatic cancer cells to treatment with gemcitabine and HER-inhibitors is accompanied by increased sensitivity to STAT3 inhibition
por: IOANNOU, NIKOLAOS, et al.
Publicado: (2016)

Treatment with a combination of the ErbB (HER) family blocker afatinib and the IGF-IR inhibitor, NVP-AEW541 induces synergistic growth inhibition of human pancreatic cancer cells
por: Ioannou, Nikolaos, et al.
Publicado: (2013)

Therapeutic Applications of Monoclonal Antibodies
por: Berger, Mitchell, et al.
Publicado: (2002)

Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy
por: Cruz-Teran, Carlos, et al.
Publicado: (2021)

Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs
por: Puvanenthiran, Soozana, et al.
Publicado: (2016)

The pharmacology and therapeutic applications of monoclonal antibodies
por: Castelli, María Sofía, et al.
Publicado: (2019)

Current and emerging therapeutic strategies in pancreatic cancer: Challenges and opportunities
por: Manrai, Manish, et al.
Publicado: (2021)

A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer
por: Modjtahedi, Helmout, et al.
Publicado: (2014)

Synergistic effects of various Her inhibitors in combination with IGF-1R, C-MET and Src targeting agents in breast cancer cell lines
por: Stanley, Aryan, et al.
Publicado: (2017)

Pancreatic cancer: challenges and opportunities
por: Zhu, Huiyun, et al.
Publicado: (2018)

Inhibitory Effects of Culinary Herbs and Spices on the Growth of HCA-7 Colorectal Cancer Cells and Their COX-2 Expression
por: Jaksevicius, Andrius, et al.
Publicado: (2017)

Therapeutic bacteria to combat cancer; current advances, challenges, and opportunities
por: Sedighi, Mansour, et al.
Publicado: (2019)

The history of monoclonal antibody development – Progress, remaining challenges and future innovations
por: Liu, Justin K.H.
Publicado: (2014)

The impact of co-expression of wild-type EGFR and its ligands determined by immunohistochemistry for response to treatment with cetuximab in patients with metastatic colorectal cancer
por: Khelwatty, Said, et al.
Publicado: (2016)

Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
por: Khelwatty, Said A, et al.
Publicado: (2015)

Advances in the applications of monoclonal antibodies in clinical oncology. Abstracts.
Publicado: (1984)

Bringing Preventive RSV Monoclonal Antibodies to Infants in Low- and Middle-Income Countries: Challenges and Opportunities
por: Ananworanich, Jintanat, et al.
Publicado: (2021)

Therapeutic use of monoclonal antibodies: general aspects and challenges for drug delivery
por: Quinteros, Daniela A., et al.
Publicado: (2017)

GNSS smartphones positioning: advances, challenges, opportunities, and future perspectives
por: Zangenehnejad, Farzaneh, et al.
Publicado: (2021)

Editorial: Immunity to Cytomegalovirus Infections: Challenges and Therapeutic Opportunities
por: Alonso-Arias, Rebeca, et al.
Publicado: (2022)

Latest Advances and Future Challenges in Pancreatic Surgery
por: Joliat, Gaëtan-Romain
Publicado: (2023)

Therapeutic monoclonal antibody for sporotrichosis
por: Almeida, Sandro R.
Publicado: (2012)

Monoclonal Antibodies as Neurological Therapeutics
por: Gklinos, Panagiotis, et al.
Publicado: (2021)

HER2 Expression Is Predictive of Survival in Cetuximab Treated Patients with RAS Wild Type Metastatic Colorectal Cancer
por: Khelwatty, Said A., et al.
Publicado: (2021)

Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
por: Ascierto, Paolo A, et al.
Publicado: (2011)

Current and Future Applications of Monoclonal Antibodies against Bacteria in Veterinary Medicine
por: SHERMAN, DAVID M., et al.
Publicado: (1986)

Co-Expression of HER Family Members in Patients with Dukes’ C and D Colon Cancer and Their Impacts on Patient Prognosis and Survival
por: Khelwatty, Said Abdullah, et al.
Publicado: (2014)

Co-expression and prognostic significance of putative CSC markers CD44, CD133, wild-type EGFR and EGFRvIII in metastatic colorectal cancer
por: Khelwatty, Said Abdullah, et al.
Publicado: (2019)

Technological Advancements in Monoclonal Antibodies
por: Santos-Neto, José F., et al.
Publicado: (2021)

Molecular profiling of ctDNA in pancreatic cancer: Opportunities and challenges for clinical application
por: Sivapalan, L., et al.
Publicado: (2021)

Current epidemiology of pancreatic cancer: Challenges and opportunities
por: Luo, Wenhao, et al.
Publicado: (2020)

Challenges and Opportunities Associated With Platelets in Pancreatic Cancer
por: Chen, Zhou, et al.
Publicado: (2022)

Pancreatic Cancer: Challenges and Opportunities in Locoregional Therapies
por: Bazeed, Alaa Y., et al.
Publicado: (2022)

The Future of Parasitology: Challenges and Opportunities
por: Elsheikha, Hany M.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_anghfc040k7pogtktta38dlsr7